These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 32723670)

  • 1. A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812 (Viloxazine Extended-release) in the Treatment of Attention-deficit/Hyperactivity Disorder in School-age Children.
    Nasser A; Liranso T; Adewole T; Fry N; Hull JT; Chowdhry F; Busse GD; Cutler AJ; Jones NJ; Findling RL; Schwabe S
    Clin Ther; 2020 Aug; 42(8):1452-1466. PubMed ID: 32723670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Once-Daily SPN-812 200 and 400 mg in the treatment of ADHD in School-aged Children: A Phase III Randomized, Controlled Trial.
    Nasser A; Liranso T; Adewole T; Fry N; Hull JT; Chowdhry F; Busse GD; Melyan Z; Cutler AJ; Findling RL; Schwabe S
    Clin Ther; 2021 Apr; 43(4):684-700. PubMed ID: 33750646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase 3 Placebo-Controlled Trial of Once-Daily 400-mg and 600-mg SPN-812 (Viloxazine Extended-Release) in Adolescents with ADHD.
    Nasser A; Liranso T; Adewole T; Fry N; Hull JT; Chowdhry F; Busse GD; Melyan Z; Cutler AJ; Findling RL; Schwabe S
    Psychopharmacol Bull; 2021 Mar; 51(2):43-64. PubMed ID: 34092822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder.
    Nasser A; Hull JT; Chaturvedi SA; Liranso T; Odebo O; Kosheleff AR; Fry N; Cutler AJ; Rubin J; Schwabe S; Childress A
    CNS Drugs; 2022 Aug; 36(8):897-915. PubMed ID: 35896943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Nasser A; Liranso T; Adewole T; Fry N; Hull JT; Busse GD; Chowdhry F; Cutler AJ; Jones NJ; Findling RL; Schwabe S
    J Clin Psychopharmacol; 2021 Jul-Aug 01; 41(4):370-380. PubMed ID: 34181360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Translating Attention-Deficit/Hyperactivity Disorder Rating Scale-5 and Weiss Functional Impairment Rating Scale-Parent Effectiveness Scores into Clinical Global Impressions Clinical Significance Levels in Four Randomized Clinical Trials of SPN-812 (Viloxazine Extended-Release) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
    Nasser A; Kosheleff AR; Hull JT; Liranso T; Qin P; Busse GD; O'Neal W; Fava M; Faraone SV; Rubin J
    J Child Adolesc Psychopharmacol; 2021 Apr; 31(3):214-226. PubMed ID: 33600233
    [No Abstract]   [Full Text] [Related]  

  • 7. A Phase II Double-Blind, Placebo-Controlled, Efficacy and Safety Study of SPN-812 (Extended-Release Viloxazine) in Children With ADHD.
    Johnson JK; Liranso T; Saylor K; Tulloch G; Adewole T; Schwabe S; Nasser A; Findling RL; Newcorn JH
    J Atten Disord; 2020 Jan; 24(2):348-358. PubMed ID: 30924702
    [No Abstract]   [Full Text] [Related]  

  • 8. Does Guanfacine Extended Release Impact Functional Impairment in Children with Attention-Deficit/Hyperactivity Disorder? Results from a Randomized Controlled Trial.
    Stein MA; Sikirica V; Weiss MD; Robertson B; Lyne A; Newcorn JH
    CNS Drugs; 2015 Nov; 29(11):953-62. PubMed ID: 26547425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early response to SPN-812 (viloxazine extended-release) can predict efficacy outcome in pediatric subjects with ADHD: a machine learning post-hoc analysis of four randomized clinical trials.
    Faraone SV; Gomeni R; Hull JT; Busse GD; Melyan Z; O'Neal W; Rubin J; Nasser A
    Psychiatry Res; 2021 Feb; 296():113664. PubMed ID: 33418457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Wilens TE; Robertson B; Sikirica V; Harper L; Young JL; Bloomfield R; Lyne A; Rynkowski G; Cutler AJ
    J Am Acad Child Adolesc Psychiatry; 2015 Nov; 54(11):916-25.e2. PubMed ID: 26506582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Executive Function Outcome of Treatment with Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Post-Hoc Analysis of Four Randomized Clinical Trials.
    Faraone SV; Gomeni R; Hull JT; Busse GD; Melyan Z; Rubin J; Nasser A
    Paediatr Drugs; 2021 Nov; 23(6):583-589. PubMed ID: 34523063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase 3, Randomized Double-Blind Study of the Efficacy and Safety of Low-Dose SHP465 Mixed Amphetamine Salts Extended-Release in Children with Attention-Deficit/Hyperactivity Disorder.
    Mattingly G; Arnold V; Yan B; Yu M; Robertson B
    J Child Adolesc Psychopharmacol; 2020 Nov; 30(9):549-557. PubMed ID: 33185468
    [No Abstract]   [Full Text] [Related]  

  • 14. A post hoc analysis of the effect of viloxazine extended-release capsules on learning and school problems in children and adolescents with attention-deficit/hyperactivity disorder.
    Faraone SV; Gomeni R; Hull JT; Busse GD; Melyan Z; Rubin J; Nasser A
    Eur Child Adolesc Psychiatry; 2023 Mar; 32(3):491-499. PubMed ID: 34581911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study.
    Wigal SB; Nordbrock E; Adjei AL; Childress A; Kupper RJ; Greenhill L
    CNS Drugs; 2015 Apr; 29(4):331-40. PubMed ID: 25877989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dasotraline in Children with Attention-Deficit/Hyperactivity Disorder: A Six-Week, Placebo-Controlled, Fixed-Dose Trial.
    Findling RL; Adler LA; Spencer TJ; Goldman R; Hopkins SC; Koblan KS; Kent J; Hsu J; Loebel A
    J Child Adolesc Psychopharmacol; 2019 Mar; 29(2):80-89. PubMed ID: 30694697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled, Forced-Dose Clinical Study.
    Weisler RH; Greenbaum M; Arnold V; Yu M; Yan B; Jaffee M; Robertson B
    CNS Drugs; 2017 Aug; 31(8):685-697. PubMed ID: 28712074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial.
    Connor DF; Findling RL; Kollins SH; Sallee F; López FA; Lyne A; Tremblay G
    CNS Drugs; 2010 Sep; 24(9):755-68. PubMed ID: 20806988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response of peer relations and social activities to treatment with viloxazine extended-release capsules (Qelbree
    Faraone SV; Gomeni R; Hull JT; Busse GD; Lujan B; Rubin J; Nasser A
    Brain Behav; 2023 Apr; 13(4):e2910. PubMed ID: 36847750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.